Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$76.7MCash on Hand
29.5mo Cash Runway
Follow IBIO by emailGet an email when IBIO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IBIO, unsubscribe in one click. Privacy
📣 What IBIO Says Is Next
first quarter of 2027 · IBIO-600: “We also anticipate advancing IBIO-600 in the multiple ascending dose portion of the Phase 1 trial in the first quarter of 2027 and progressing our preclinical programs that aim to address the entire spectrum of cardiometabolic disease care.”
Company press release, Nov 10, 2026 · SEC filing
first half of 2027 · IBIO-610: ““The data presented at EASD strengthen our conviction in IBIO-610’s potential to deliver high-quality weight loss and provide important preclinical validation as we advance toward an IND-equivalent filing by the end of 2026, with plans to initiate first-in-human studies in the first half of 2027.”
Company press release, Nov 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Clinical trial Extended 28-week NHP data for IBIO-610 showed a 2.3% body weight reduction versus vehicle at week 28, with 9.6% lower total fat at week 24. Preclinical amylin data showing reduced food intake in rats will be presented at upcoming conferences. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Earnings Reported Q1 fiscal 2027 revenue of $1,075K vs $100K a year earlier, R&D expenses of $6,650K vs $3,550K, and a net loss of $7,551K vs $5,720K. Cash and investments were $76.7 million as of September 30, 2026. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 19, 2026 ·
Shareholder vote Stockholders approved an amendment to the 2023 Omnibus Incentive Plan with annual share increases through 2033, and an increase in authorized common stock from 275,000,000 to 500,000,000 shares, effective October 16, 2026. William Clark and Gary Sender were elected Class III directors. Form 8-K · SEC filing
Oct 13, 2026 ·
Clinical trial iBio presented preclinical data showing IBIO-610 plus semaglutide led to 93% of weight lost being fat at week 8 in obese non-human primates, versus 77% with semaglutide alone. Lean mass was 6% of weight lost versus 22%. First-in-human studies are planned for the first half of 2027. Form 8-K · SEC filing · Press release
Sep 14, 2026 ·
iBio updated its corporate presentation for investor and analyst meetings, filed as Exhibit 99.1. The presentation outlines its obesity antibody pipeline and anticipated near-term milestones, including an IBIO-610 IND-equivalent filing in 2H 2026 and IBIO-600 interim Phase 1 data in 1Q 2027. Form 8-K · SEC filing · Press release
Sep 4, 2026 ·
Shareholder vote Annual meeting set for October 14, 2026 in San Diego. Shareholders will vote on electing two Class III directors, ratifying Grassi & Co., CPAs as auditor, a say-on-pay advisory vote, raising authorized common stock to 500,000,000 shares, and amending the 2023 Omnibus Incentive Plan's evergreen provision. Form DEF 14A · SEC filing
Aug 28, 2026 ·
Earnings Reported fiscal 2026 results with revenue of about $0.1 million, R&D expenses of $19.6 million and G&A of $10.6 million, plus a $5.0 million impairment of IBIO-101 intangible assets. Cash and investments were about $88.0 million at June 30, 2026, with runway said to extend into fiscal 2028. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2027 · Phase 1 · Recruiting · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults Registry primary completion date, not a results date
Jan 2028 · Phase 1 · Upcoming Trial · A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity. Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
IBIO holds $76.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.8M/quarter from operations,
an estimated runway of 29.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:35 · Moderate
Cash runway 30 months
ATM program on file since Mar 2026 +15
Shelf registration (S-3, Feb 2026) +10
Company says cash lasts into the fourth quarter of fiscal year 2028 -10Our current cash, cash equivalents and investments in debt securities of approximately $76.7 million as of September 30, 2026, is anticipated to be sufficient to support operations into the fourth quarter of fiscal year 2028.10-Q, Nov 2026
Share count 70,455,809 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full IBIO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IBIO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.